Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.
about
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemicNuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.Temporal relationship between diet-induced steatosis and onset of insulin/leptin resistance in male Wistar rats.Iron Status and Metabolic Syndrome in Patients with Non-Alcoholic Fatty Liver Disease.Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial.Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.Should we rely on the findings of each published randomized controlled study?Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysisEffects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trialsPotential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD
P2860
Q24563381-AEABF5C9-B32D-4CE7-A3D3-14669C1EA94CQ28066233-FDD23161-4CEB-48F3-87B6-28051D369AF1Q34061979-D729A7C5-5CAE-4DF3-836F-FD6820690F24Q35556717-6390BD92-8F9C-4F6D-A770-89F4436DFF3AQ36636361-8D2492E4-097B-4B6B-9E30-B250954B026EQ37488906-A730678E-0B37-400F-B192-658BCAA8F1B9Q38192049-6DB868D7-2843-4BB0-8708-DF9670998787Q38867031-6E03F699-B4A6-4202-B9B7-1520379D51A0Q40406924-C555A95C-4B3F-46E7-ADF2-0033E57D1326Q41122488-9560B4DD-62AA-4B71-B6F5-5E05E98FF14BQ41623607-030E2AC3-1BC0-4BC2-AD6D-EEDAC6B0F551Q43427762-9C2ACAEC-6C37-46AA-AC93-8E7C12F3B9F3Q44037507-12EFDBF4-CEAB-4BF8-A01A-B074A30A6973Q47132791-46DE6648-48FC-4C14-805E-BBA86B9C01A5Q48152092-F74394EC-9B20-4C01-BB66-070697D1BF72Q58739768-604268DF-7799-45D4-B13D-0C7024B3C4A5Q58753073-70B0C8C3-8BDA-4721-8515-5B4B331CFBED
P2860
Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Effects of metformin, pioglita ...... omized controlled pilot study.
@ast
Effects of metformin, pioglita ...... omized controlled pilot study.
@en
type
label
Effects of metformin, pioglita ...... omized controlled pilot study.
@ast
Effects of metformin, pioglita ...... omized controlled pilot study.
@en
prefLabel
Effects of metformin, pioglita ...... omized controlled pilot study.
@ast
Effects of metformin, pioglita ...... omized controlled pilot study.
@en
P2093
P2860
P356
P1433
P1476
Effects of metformin, pioglita ...... omized controlled pilot study.
@en
P2093
Ali Akbar Hajiaghamohammadi
Amir Ziaee
Homa Masroor
Sonia Oveisi
P2860
P356
10.5812/HEPATMON.6099
P407
P577
2012-08-03T00:00:00Z